{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:18:19Z","timestamp":1788556699422,"version":"build-2803163510"},"reference-count":91,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Lymph node involvement in prostate cancer has major prognostic and therapeutic implications, yet conventional imaging based on size and morphology remains limited in detecting small-volume metastatic disease. Although extended pelvic lymph node dissection is considered the reference standard for nodal staging, it is invasive, associated with morbidity, and primarily diagnostic in intent. Prostate-specific membrane antigen positron emission tomography (PSMA PET) has reshaped staging by enabling molecular detection of nodal metastases, consistently demonstrating superior accuracy compared with conventional imaging. This narrative review critically evaluates the role of PSMA PET in lymph node staging, with a primary focus on primary diagnosis and selected considerations on biochemical recurrence, focusing not only on diagnostic accuracy but on clinical utility and decision-making. PSMA PET shows high specificity but moderate sensitivity for pelvic nodal metastases, with reduced performance for micrometastatic disease; therefore, a negative scan cannot reliably exclude nodal involvement in high-risk patients. Evidence indicates frequent stage migration and management changes, including refinement of surgical planning, radiotherapy target delineation, and treatment intensification strategies. However, most pivotal therapeutic trials were based on conventional imaging, and long-term outcome data validating PSMA PET-guided treatment adaptations remain limited. We discuss biological rationale, radiotracer characteristics, interpretation frameworks, guideline perspectives, real-world variability in adoption, and current limitations, including false-positive findings, PSMA heterogeneity, and lack of universal standardization. Rather than replacing established staging paradigms, PSMA PET should be integrated within a comprehensive, risk-adapted framework. Ongoing prospective trials will clarify whether molecularly defined nodal staging translates into improved oncologic outcomes and will determine its definitive role in contemporary prostate cancer management.<\/jats:p>","DOI":"10.3390\/cancers18132094","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:16:44Z","timestamp":1782699404000},"page":"2094","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0108-1864","authenticated-orcid":false,"given":"Francesco","family":"Esperto","sequence":"first","affiliation":[{"name":"Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico of Rome, 00128 Rome, Italy"},{"name":"Research Unit of Urology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8313-6619","authenticated-orcid":false,"given":"Arianna","family":"Pischetola","sequence":"additional","affiliation":[{"name":"Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico of Rome, 00128 Rome, Italy"},{"name":"Research Unit of Urology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1937-9116","authenticated-orcid":false,"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy"},{"name":"IRCCS Azienda Ospedaliera Metropolitana, 16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5381-2668","authenticated-orcid":false,"given":"Jacopo","family":"Passoni","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Testa","sequence":"additional","affiliation":[{"name":"Department of Urology, San Camillo De Lellis Hospital, ASL of Rieti, 02100 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-5632","authenticated-orcid":false,"given":"Stefania","family":"Ferretti","sequence":"additional","affiliation":[{"name":"Urology Unit, Azienda Ospedaliero-Universitaria of Modena, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1597-9595","authenticated-orcid":false,"given":"Stefano","family":"Puliatti","sequence":"additional","affiliation":[{"name":"Urology Unit, Azienda Ospedaliero-Universitaria of Modena, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":false,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-6310","authenticated-orcid":false,"given":"Roberto Mario","family":"Scarpa","sequence":"additional","affiliation":[{"name":"Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico of Rome, 00128 Rome, Italy"},{"name":"Research Unit of Urology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2072-114X","authenticated-orcid":false,"given":"Davide","family":"Campobasso","sequence":"additional","affiliation":[{"name":"Department of Urology, San Camillo De Lellis Hospital, ASL of Rieti, 02100 Rome, Italy"},{"name":"Ph.D. Program in Learning Sciences and Digital Technologies, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-7243","authenticated-orcid":false,"given":"Rocco","family":"Papalia","sequence":"additional","affiliation":[{"name":"Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico of Rome, 00128 Rome, Italy"},{"name":"Research Unit of Urology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1007\/s11255-025-04450-0","article-title":"Metastatic lymph nodes outside the extended lymphadenectomy template correlate with advanced staging but not grading in prostate cancer patients undergoing radical prostatectomy","volume":"57","author":"Karwacki","year":"2025","journal-title":"Int. Urol. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bco2.73","article-title":"M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting","volume":"2","author":"Aluwini","year":"2021","journal-title":"BJUI Compass"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2967\/jnumed.119.228320","article-title":"Multimodality Imaging of Prostate Cancer","volume":"60","author":"Ghafoor","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_7","unstructured":"Memorial Sloan Kettering Cancer Center (2026, February 10). Prostate Cancer Nomograms: Pre-Radical Prostatectomy. Available online: https:\/\/www.mskcc.org\/nomograms\/prostate\/pre_op."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ma\u0142kiewicz, B., Kie\u0142b, P., Karwacki, J., Czerwi\u0144ska, R., D\u0142ugosz, P., Lemi\u0144ski, A., Nowak, \u0141., Krajewski, W., and Szyde\u0142ko, T. (2022). Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand? . J. Clin. Med., 11.","DOI":"10.20944\/preprints202203.0197.v1"},{"key":"ref_9","first-page":"73","article-title":"Comparison of perioperative complications for extended vs standard pelvic lymph node dissection in patients undergoing radical prostatectomy for prostate cancer: A meta-analysis","volume":"10","author":"Kong","year":"2022","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"von Stauffenberg, F., Poyet, C., Beintner-Skawran, S., Maurer, A., and Schmid, F.A. (2024). Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. Cancers, 16.","DOI":"10.3390\/cancers16244263"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.euo.2024.11.006","article-title":"Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography\/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial","volume":"9","author":"Hofman","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.eururo.2023.06.022","article-title":"Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial","volume":"84","author":"Armstrong","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: A multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.eururo.2025.04.017","article-title":"Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study","volume":"88","author":"Karpinski","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"175628722513219717","DOI":"10.1177\/17562872251321971","article-title":"The expanding role of next-generation imaging in prostate cancer management: A cross-sectional survey exploring the clinical practice of uro-oncologists in North-Eastern Italy; on behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est)","volume":"17","author":"Matrone","year":"2025","journal-title":"Ther. Adv. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40336-025-00740-w","article-title":"Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: Technical aspects and primary staging setting","volume":"14","author":"Bauckneht","year":"2025","journal-title":"Clin. Transl. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sandhu, K., Chen, D., Hennes, D., Murphy, D.G., Lawrentschuk, N., and Perera, M. (2025). PSMA Theranostics in Prostate Cancer and Beyond: Current and Future Perspectives. Cancers, 17.","DOI":"10.3390\/cancers17223717"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Maes, J., Gesqui\u00e8re, S., De Spiegeleer, A., Maes, A., and Van de Wiele, C. (2024). Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179755"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/bjr\/tqae092","article-title":"Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands","volume":"97","author":"Naik","year":"2024","journal-title":"Br. J. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA Ligands for PET Imaging of Prostate Cancer","volume":"58","author":"Schwarzenboeck","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s11912-025-01682-2","article-title":"The Evolving Role of PSMA-PET\/CT in Prostate Cancer Management: An Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact","volume":"27","author":"Wang","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer\u2014A systematic review and meta-analysis","volume":"27","author":"Huang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","unstructured":"Vyas, M., Henderson, A.M., and Leslie, S.W. (2026, April 14). Nuclear Medicine Applications in Prostate Cancer, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK592382\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e229008","DOI":"10.1148\/rycan.229008","article-title":"Pelvic Nodal Metastasis Detection with 68Ga-PSMA-11 PET Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection","volume":"4","author":"Sadaghiani","year":"2022","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s00345-020-03131-0","article-title":"68Ga-PSMA PET\/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy","volume":"38","author":"Kopp","year":"2020","journal-title":"World J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00330-023-09516-0","article-title":"Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET\/CT for biochemical recurrent prostate cancer: A clinical practice-oriented study","volume":"33","author":"Bauckneht","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.12688\/hrbopenres.13801.2","article-title":"Diagnostic accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: Protocol for an overview of reviews","volume":"6","author":"Dullea","year":"2025","journal-title":"HRB Open Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2967\/jnumed.119.229187","article-title":"Matched-Pair Comparison of 68Ga-PSMA-11 PET\/CT and 18F-PSMA-1007 PET\/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JU.0000000000003598","article-title":"Diagnostic Performance and Safety of 18 F-rhPSMA-7.3 Positron Emission Tomography in Men with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)","volume":"210","author":"Jani","year":"2023","journal-title":"Reply. J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines in Oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","article-title":"Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard","volume":"5","author":"Stabile","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.prnil.2025.02.001","article-title":"Pelvic lymph node management in prostate cancer: A narrative review","volume":"13","author":"Chong","year":"2025","journal-title":"Prostate Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euf.2025.01.015","article-title":"Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy","volume":"11","author":"Incesu","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1016\/j.acra.2024.11.029","article-title":"PSMA PET vs. mpMRI for Lymph Node Metastasis of Prostate Cancer: A Systematic Review and Head-to-Head Comparative Meta-analysis","volume":"32","author":"Yang","year":"2025","journal-title":"Acad. Radiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.eururo.2025.03.003","article-title":"A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment","volume":"87","author":"Mazzone","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21037\/cco-23-10","article-title":"Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit","volume":"12","author":"Maestroni","year":"2023","journal-title":"Chin. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00432-025-06184-z","article-title":"PSMA PET\/CT for prostate cancer diagnosis: Current applications and future directions","volume":"151","author":"Shen","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","article-title":"Pelvic lymph-node staging with 18F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer\u2014The SALT trial-","volume":"48","author":"Jansen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.semnuclmed.2023.02.006","article-title":"Histopathologically Validated Diagnostic Accuracy of PSMA-PET\/CT in the Primary and Secondary Staging of Prostate Cancer and the Impact of PSMA-PET\/CT on Clinical Management: A Systematic Review and Meta-analysis","volume":"53","author":"Jeet","year":"2023","journal-title":"Semin. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Bianchi, L., Droghetti, M., Catanzaro, C., Valerio, M., Novello, Q., Mari, A., Campi, R., Nicoletti, R., Heidegger, I., and Giannini, G. (Eur. Urol. Oncol., 2025). Prostate-specific Membrane Antigen Positron Emission Tomography Versus Conventional Imaging for Preoperative Staging High-risk Prostate Cancer Patients Undergoing Surgery for cN0M0 Disease: An European Association of Urology\u2014Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study, Eur. Urol. Oncol., in press.","DOI":"10.1016\/j.euo.2025.11.011"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.23736\/S2724-6051.25.06470-5","article-title":"The added value of PSMA PET to nomograms in identifying optimal candidates for extended pelvic lymph node dissection in intermediate-risk prostate cancer patients","volume":"77","author":"Bauckneht","year":"2025","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41391-024-00930-z","article-title":"Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer","volume":"28","author":"Incesu","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.euo.2023.05.003","article-title":"Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool","volume":"6","author":"Gandaglia","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euo.2023.03.010","article-title":"Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography","volume":"6","author":"Vis","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.euo.2020.04.004","article-title":"PSMA-PET\/CT\u2013based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy","volume":"4","author":"Schiller","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/j.semnuclmed.2025.03.006","article-title":"Impact of PSMA PET on Radiation Oncology Planning","volume":"55","author":"Spohn","year":"2025","journal-title":"Semin. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/a-2284-0593","article-title":"Impact of 68Ga-PSMA PET\/CT on radiation treatment planning of prostate cancer patients","volume":"63","author":"Bock","year":"2024","journal-title":"Nuklearmedizin"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00345-025-05950-5","article-title":"PSMA-PET\/CT-based salvage elective nodal radiotherapy for lymph node recurrence following radical prostatectomy","volume":"43","author":"Vorbach","year":"2025","journal-title":"World J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ijrobp.2022.12.055","article-title":"PSMA-PET\/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial","volume":"116","author":"Petit","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Calais, J., Zhu, S., Hirmas, N., Eiber, M., Hadaschik, B., Stuschke, M., Herrmann, K., Czernin, J., Kishan, A.U., and Nickols, N.G. (2021). Phase 3 multicenter randomized trial of PSMA PET\/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08026-w"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.18383\/j.tom.2018.00021","article-title":"Pitfalls in Gallium-68 PSMA PET\/CT Interpretation\u2014A Pictorial Review","volume":"4","author":"Shetty","year":"2018","journal-title":"Tomography"},{"key":"ref_63","unstructured":"Burger, I., and Sayyid, R.K. (2026, April 15). APCCC Diagnostics 2025: False Positive PSMA PET: What to Know? 2026. Available online: https:\/\/www.urotoday.com\/conference-highlights\/apccc-diagnostics-2025\/158672-apccc-diagnostics-2025-false-positive-psma-pet-what-to-know.html."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","article-title":"The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: A systematic review-based definition","volume":"51","author":"Rizzo","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","article-title":"Focal unspecific bone uptake on [18F]-PSMA-1007 PET: A multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging","volume":"48","author":"Maurer","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-020-00300-7","article-title":"Nonprostatic diseases on PSMA PET imaging: A spectrum of benign and malignant findings","volume":"20","author":"Barbosa","year":"2020","journal-title":"Cancer Imaging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"23902","DOI":"10.1038\/s41598-025-06393-z","article-title":"Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases","volume":"15","author":"Mulati","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Mantica, G., Chierigo, F., Ambrosini, F., D\u2019amico, F., Celesti, G., Ferrari, A., Gallo, F., Schenone, M., Benelli, A., and Introini, C. (2025). Interpretation of PSMA-PET Among Urologists: A Prospective Multicentric Evaluation. Cancers, 17.","DOI":"10.3390\/cancers17132122"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00261-025-05068-7","article-title":"PSMA-RADS 2.0: A revised framework for PSMA-targeted imaging interpretation and clinical decision-making","volume":"51","author":"Elsamny","year":"2025","journal-title":"Abdom. Radiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","article-title":"PSMA PET\/CT for Primary Staging of Prostate Cancer\u2014An Updated Overview","volume":"54","author":"Jochumsen","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wang, Y., Jing, R., Wang, H., and Zhao, Q. (2024). 68Ga-PSMA-11 PET and mpMRI in the diagnosis of initial lymph node staging of prostate cancer: A head-to-head comparative meta-analysis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1425134"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s00259-025-07190-6","article-title":"A cost-effectiveness study of PSMA-PET\/CT for the detection of clinically significant prostate cancer","volume":"52","author":"Govers","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","article-title":"Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET\/CT","volume":"44","author":"Schwenck","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Milojevic, I.G., Milojevic, B., Skrijelj, D., Bumbasirevic, U., Janicic, A., Kajmakovic, B., Sobic-Saranovic, D., Artiko, V., and Beatovic, S. (2025). The Role of Nuclear Medicine in Prostate Cancer. Diagnostics, 15.","DOI":"10.3390\/diagnostics15222876"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00259-021-05296-1","article-title":"Prospective comparison of 18F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer","volume":"48","author":"Malaspina","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"20210728","DOI":"10.1259\/bjr.20210728","article-title":"Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET\u2013CT vs PET\u2013MRI","volume":"95","author":"Liu","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40644-022-00518-7","article-title":"Variability of radiotherapy volume delineation: PSMA PET\/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer","volume":"23","author":"Liu","year":"2023","journal-title":"Cancer Imaging"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Urso, L., Badrane, I., Manco, L., Castello, A., Lancia, F., Collavino, J., Crestani, A., Castellani, M., Cittanti, C., and Bartolomei, M. (2025). The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness. J. Clin. Med., 14.","DOI":"10.3390\/jcm14103318"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Santucci, D., Ragone, R., Vergantino, E., Vaccarino, F., Esperto, F., Prata, F., Scarpa, R.M., Papalia, R., Zobel, B.B., and Grasso, F.R. (2024). Comparison between Three Radiomics Models and Clinical Nomograms for Prediction of Lymph Node Involvement in PCa Patients Combining Clinical and Radiomic Features. Cancers, 16.","DOI":"10.3390\/cancers16152731"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e210091","DOI":"10.1148\/rycan.210091","article-title":"18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"4","author":"Yadav","year":"2022","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer","volume":"62","author":"Baratto","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez, R., Soza-Ried, C., Iagaru, A., Stephens, A., M\u00fcller, A., Schieferstein, H., Sandoval, C., Amaral, H., and Kramer, V. (2023). Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [68Ga]Ga-RM2\u2014A Head-to-Head Pilot Comparison with [68Ga]Ga-PSMA-11. Cancers, 16.","DOI":"10.3390\/cancers16010173"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euf.2025.05.003","article-title":"Radioguided Surgery for Prostate Cancer","volume":"11","author":"Quarta","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1007\/s00259-026-07773-x","article-title":"Diagnostic accuracy of PSMA-targeted radioguided surgery in prostate cancer at multiple anatomical levels: A systematic review and meta-analysis","volume":"53","author":"Wen","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1007\/s00259-025-07623-2","article-title":"[99mTc]Tc-PSMA-HSG for PSMA-targeted Hybrid Surgical Guidance: A new addition to the PSMA-I&S\/I&T family","volume":"53","author":"Schottelius","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): Secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2094\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:42:02Z","timestamp":1783413722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":91,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132094"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132094","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]}}}